Could a painkiller improve breathing in lung scarring?
NCT ID NCT07036029
First seen Jan 25, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This early-stage study is testing a drug called nalbuphine ER in 10 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease that makes breathing hard. The goal is to see if the drug is safe and can improve breathing function. Participants will take increasing doses of the medication while their breathing and oxygen levels are closely monitored in a clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Medicines Evaluation Unit Ltd.
RECRUITINGManchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.